CCCC
C4 TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Operationally, the story has improved since the prior baseline: MOMENTUM has started, the elranatamab combination trial has dosed its first patient, and Roche added a fresh collaboration with upfront cash and milestone optionality. For a company with a market cap near $286 million, those are real execution markers rather than hypothetical roadmap items.
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +7.1.
What can break
As of May 8, 2026, no confirmed Q1 2026 earnings release or 10-Q was found in recent company IR postings or SEC recent filings, leaving an important cash-burn and quarterly-update gap.
Momentum
94
Value
41
Sentiment
25
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.10 · Bull $5.00 · Bear $1.70
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $11.57
Why
Momentum94 · Δ7d +7.1
Value41 · Δ7d +0.1
Sentiment25 · Δ7d -15.0
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
94
34% active weight
Current posture
7d trendImproving
Δ7d
+7.1
Δ21d
+20.6
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
25
33% active weight
Current posture
7d trendSoftening
Δ7d
-15.0
Δ21d
-22.1
Why this grade
Composite grade C. Momentum 94.0 / Value 41.1 / Sentiment 24.9
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$484.28M
Beta
2.97
Shares Out
96.91M
P/E (TTM) · Derived
-3.9
P/S (TTM)
6.53
P/FCF (TTM) · Derived
-3.75
Rev YoY
-26.9%
EPS YoY
-25.1%
Gross Margin
-
Op Margin
-431.1%
Net Debt
-$244.9M
Current Ratio
5.75
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology